19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cervical cancer Histone deacetylase 10 (HDAC10) Patient tissue and mouse studies suggest increasing HDAC10 activity could help prevent cervical cancer metastasis. In an analysis of...
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Neuroendocrine tumors Histone deacetylase 10 (HDAC10) Computational and cell culture studies suggest HDAC10 inhibitors could enhance chemotherapy in treating neuroblastoma. In...
07:00 , Apr 4, 2013 |  BC Innovations  |  Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...